Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 5Breast Neoplasms 5Pancreatic Neoplasms 3Rectal Neoplasms 2Prostatic Neoplasms 2Neoplasms 2Multiple Myeloma 2Lung Neoplasms 2Hematologic Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1

Interventions

pembrolizumab 3spartalizumab 2sargramostim 2trametinib 1tislelizumab 1nazartinib 1fludarabine phosphate 1enzalutamide 1canakinumab 1bemarituzumab 1Specimen Handling 1Midazolam 1Magnetic Resonance Spectroscopy 1Letrozole 1Interleukin-13 1IFL protocol 1Fulvestrant 1Fluorodeoxyglucose F18 1Cyclophosphamide 1Cetuximab 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × trametinib × Breast × Clear all
NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)

Novartis

Phase 1 Completed
283 enrolled
BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔